

Stephen E Gitelman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9185605/publications.pdf>

Version: 2024-02-01

27
papers

4,274
citations

430442

18
h-index

525886

27
g-index

29
all docs

29
docs citations

29
times ranked

4122
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report. <i>Diabetes</i> , 2021, 70, 1123-1129.	0.3	11
2	Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. <i>Diabetologia</i> , 2021, 64, 2432-2444.	2.9	8
3	Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 502-514.	5.5	53
4	Continuous Glucose Monitoring to Diagnose Hypoglycemia Due to Late Dumping Syndrome in Children After Gastric Surgeries. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa197.	0.1	6
5	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 5-12.	4.3	220
6	Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 948-953.	2.4	41
7	Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2045-2054.	2.2	13
8	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 603-613.	13.9	584
9	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. <i>Diabetes</i> , 2019, 68, 1267-1276.	0.3	80
10	Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables. <i>Diabetologia</i> , 2019, 62, 33-40.	2.9	22
11	Type 1 Diabetes and Celiac Disease: Causal Association or True, True, Unrelated?. <i>Pediatrics</i> , 2017, 140, .	1.0	1
12	A new familial form of a late-onset, persistent hyperinsulinemic hypoglycemia of infancy caused by a novel mutation in <i>KCNJ11</i> . <i>Channels</i> , 2017, 11, 636-647.	1.5	8
13	The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4596-4603.	1.8	20
14	Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, e76-e78.	4.3	1
15	Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. <i>Diabetes</i> , 2016, 65, 3765-3775.	0.3	62
16	Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 2218-2224.	4.3	25
17	Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. <i>Diabetes Care</i> , 2015, 38, 1975-1985.	4.3	68
18	Type 1 diabetes immunotherapy using polyclonal regulatory T cells. <i>Science Translational Medicine</i> , 2015, 7, 315ra189.	5.8	767

#	ARTICLE	IF	CITATIONS
19	Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. <i>Journal of Clinical Investigation</i> , 2015, 125, 3285-3296.	3.9	228
20	Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies. <i>Diabetes</i> , 2014, 63, 3120-3127.	0.3	11
21	Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial. <i>Diabetes</i> , 2013, 62, 3766-3774.	0.3	303
22	Fall in C-Peptide During First 2 Years From Diagnosis. <i>Diabetes</i> , 2012, 61, 2066-2073.	0.3	270
23	Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2011, 378, 412-419.	6.3	493
24	Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. <i>New England Journal of Medicine</i> , 2009, 361, 2143-2152.	13.9	900
25	Nephrogenic Syndrome of Inappropriate Antidiuresis: A Novel Disorder in Water Balance in Pediatric Patients. <i>American Journal of Medicine</i> , 2006, 119, S54-S58.	0.6	34
26	Structure and sequence of the mouse <i>bmp6</i> gene. <i>Mammalian Genome</i> , 1997, 8, 212-214.	1.0	15
27	Mental retardation locus in Xp21 chromosome microdeletion. <i>American Journal of Medical Genetics Part A</i> , 1993, 46, 363-368.	2.4	30